Compare VCEL & MGNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VCEL | MGNI |
|---|---|---|
| Founded | 1989 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.1B |
| IPO Year | 1997 | N/A |
| Metric | VCEL | MGNI |
|---|---|---|
| Price | $37.76 | $15.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $57.50 | $27.67 |
| AVG Volume (30 Days) | 518.5K | ★ 2.1M |
| Earning Date | 02-26-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 236.54 | 219.02 |
| EPS | 0.25 | ★ 0.38 |
| Revenue | $258,716,999.00 | ★ $702,565,000.00 |
| Revenue This Year | $17.86 | $2.07 |
| Revenue Next Year | $18.55 | $10.90 |
| P/E Ratio | $153.48 | ★ $40.61 |
| Revenue Growth | ★ 14.05 | 6.27 |
| 52 Week Low | $29.24 | $8.22 |
| 52 Week High | $63.00 | $26.65 |
| Indicator | VCEL | MGNI |
|---|---|---|
| Relative Strength Index (RSI) | 50.19 | 46.05 |
| Support Level | $35.85 | $13.80 |
| Resistance Level | $39.48 | $15.95 |
| Average True Range (ATR) | 1.89 | 0.83 |
| MACD | 0.00 | -0.10 |
| Stochastic Oscillator | 32.73 | 41.83 |
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
Magnite is a supply-side advertising platform that provides technology and yield management solutions to content publishers, enabling them to monetize their digital advertising inventory. Magnite receives a percentage of all advertising inventory that it sells. 43% of Magnite's revenue is derived from connected television, or CTV, streaming platforms, 40% from mobile applications, and the remainder from general websites. Beyond the typical monetization responsibilities inherent to an SSP, Magnite also provides upstream advertising servers to CTV publishers, allowing them to have granular control over direct-sold, programmatic guaranteed, and open-auction logic. Magnite competes with other independent SSPs, supply path optimization solutions, and closed ecosystems like Meta.